Adverse childhood experiences, DNA methylation age acceleration, and cortisol in UK children: a prospective population-based cohort study.


Journal

Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977

Informations de publication

Date de publication:
07 04 2020
Historique:
received: 27 11 2019
accepted: 26 03 2020
entrez: 9 4 2020
pubmed: 9 4 2020
medline: 4 6 2021
Statut: epublish

Résumé

Epigenetic mechanisms may partly explain the persistent effects of adverse childhood experiences (ACEs) on health outcomes in later life. DNA methylation can predict chronological age, and advanced methylation-predicted age beyond chronological age (DNA methylation age acceleration) is associated with ACEs, adverse mental and physical health, and elevated diurnal and baseline salivary cortisol. Childhood adversity is also associated with dysregulation of the hypothalamic-pituitary-adrenal axis, which produces the neuroendocrine hormone cortisol. It remains unknown whether these associations are specific to certain types of adversity. Herein, we investigate the associations of ACEs with DNA methylation age acceleration and plasma cortisol in the Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort. In this study of the children in ALSPAC, we used multiple linear regression to examine associations of cumulative exposure to ACE, as well as exposure to ten individual types of ACEs, with Horvath-estimated DNA methylation age acceleration and with baseline plasma cortisol. The ten ACEs were those included in the World Health Organization's ACE International Questionnaire. Data on ACEs were prospectively collected from age 0-14 years. DNA methylation age acceleration and plasma cortisol were measured at mean 17.1 years and 15.5 years, respectively. We included 974 UK children in the present study. Exposure to four or more ACEs compared to zero was associated with DNA methylation age acceleration in girls (β, 95% CI = 1.65, 0.25 to 3.04 years) but not in boys (β, 95% CI = - 0.11, - 1.48 to 1.26 years). Also, in girls, emotional abuse and physical abuse were each associated with DNA methylation age acceleration (β, 95% CI = 1.20, 0.15 to 2.26 years and β, 95% CI = 1.22, 0.06 to 2.38 years, respectively). No other ACEs were associated with accelerated DNA methylation age in either sex. Associations were also null between ACE and cortisol, and cortisol and DNA methylation age acceleration. In this prospective population-based study of UK children, cumulative ACE exposure, emotional abuse, and physical abuse between age 0 and 14 years were each associated with Horvath-estimated DNA methylation age acceleration at age 17 years in girls but not in boys.

Sections du résumé

BACKGROUND
Epigenetic mechanisms may partly explain the persistent effects of adverse childhood experiences (ACEs) on health outcomes in later life. DNA methylation can predict chronological age, and advanced methylation-predicted age beyond chronological age (DNA methylation age acceleration) is associated with ACEs, adverse mental and physical health, and elevated diurnal and baseline salivary cortisol. Childhood adversity is also associated with dysregulation of the hypothalamic-pituitary-adrenal axis, which produces the neuroendocrine hormone cortisol. It remains unknown whether these associations are specific to certain types of adversity. Herein, we investigate the associations of ACEs with DNA methylation age acceleration and plasma cortisol in the Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort.
METHODS
In this study of the children in ALSPAC, we used multiple linear regression to examine associations of cumulative exposure to ACE, as well as exposure to ten individual types of ACEs, with Horvath-estimated DNA methylation age acceleration and with baseline plasma cortisol. The ten ACEs were those included in the World Health Organization's ACE International Questionnaire. Data on ACEs were prospectively collected from age 0-14 years. DNA methylation age acceleration and plasma cortisol were measured at mean 17.1 years and 15.5 years, respectively.
RESULTS
We included 974 UK children in the present study. Exposure to four or more ACEs compared to zero was associated with DNA methylation age acceleration in girls (β, 95% CI = 1.65, 0.25 to 3.04 years) but not in boys (β, 95% CI = - 0.11, - 1.48 to 1.26 years). Also, in girls, emotional abuse and physical abuse were each associated with DNA methylation age acceleration (β, 95% CI = 1.20, 0.15 to 2.26 years and β, 95% CI = 1.22, 0.06 to 2.38 years, respectively). No other ACEs were associated with accelerated DNA methylation age in either sex. Associations were also null between ACE and cortisol, and cortisol and DNA methylation age acceleration.
CONCLUSIONS
In this prospective population-based study of UK children, cumulative ACE exposure, emotional abuse, and physical abuse between age 0 and 14 years were each associated with Horvath-estimated DNA methylation age acceleration at age 17 years in girls but not in boys.

Identifiants

pubmed: 32264940
doi: 10.1186/s13148-020-00844-2
pii: 10.1186/s13148-020-00844-2
pmc: PMC7137290
doi:

Substances chimiques

Hydrocortisone WI4X0X7BPJ

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

55

Subventions

Organisme : Biotechnology and Biological Sciences Research Council
ID : BBI025751/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_19009
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/I025263/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M020894/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_15018
Pays : United Kingdom
Organisme : Medical Research Council
ID : 102215/2/13/2
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 102215/2/13/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12013/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00011/5
Pays : United Kingdom

Références

Int J Epidemiol. 2015 Aug;44(4):1181-90
pubmed: 25991711
Am J Epidemiol. 2018 Nov 1;187(11):2346-2354
pubmed: 30060108
Sci Rep. 2017 Aug 21;7(1):8962
pubmed: 28827677
Wellcome Open Res. 2018 Aug 30;3:106
pubmed: 30569020
Soc Psychiatry Psychiatr Epidemiol. 2013 Jan;48(1):81-93
pubmed: 22592537
Oncotarget. 2017 Apr 4;8(14):23237-23245
pubmed: 28423572
Arch Gen Psychiatry. 2005 Jun;62(6):593-602
pubmed: 15939837
Am J Psychiatry. 2001 Nov;158(11):1878-83
pubmed: 11691695
Prev Med. 2003 Sep;37(3):268-77
pubmed: 12914833
Am J Epidemiol. 2018 Mar 1;187(3):529-538
pubmed: 29020168
Biol Psychiatry. 2019 Feb 1;85(3):268-278
pubmed: 30391001
Genome Biol. 2013;14(10):R115
pubmed: 24138928
Child Abuse Negl. 2017 Feb;64:47-60
pubmed: 28027464
Hum Mol Genet. 2016 Jan 1;25(1):191-201
pubmed: 26546615
Nat Rev Genet. 2018 Jun;19(6):371-384
pubmed: 29643443
JAMA Pediatr. 2019 Nov 4;:1-11
pubmed: 31682707
J Child Psychol Psychiatry. 2016 May;57(5):566-74
pubmed: 26680699
J Clin Epidemiol. 2019 Jun;110:63-73
pubmed: 30878639
Circ Genom Precis Med. 2018 Mar;11(3):e001937
pubmed: 29555670
BMC Med Res Methodol. 2009 Jul 28;9:57
pubmed: 19638200
Transl Psychiatry. 2017 Aug 29;7(8):e1223
pubmed: 28850111
BMJ Paediatr Open. 2019 Jan 31;3(1):e000340
pubmed: 30815585
Brain Behav Immun. 2016 Mar;53:234-241
pubmed: 26718449
Mol Cell. 2013 Jan 24;49(2):359-367
pubmed: 23177740
Int J Epidemiol. 2013 Feb;42(1):111-27
pubmed: 22507743
PLoS Med. 2010 Oct 26;7(10):e1000356
pubmed: 21048988
Transl Psychiatry. 2018 Dec 3;8(1):266
pubmed: 30510187
Genome Biol. 2016 Aug 11;17(1):171
pubmed: 27511193
Genome Biol. 2015 May 13;16:96
pubmed: 25968125
Lancet Public Health. 2018 Jun;3(6):e262-e263
pubmed: 29776799
J Child Psychol Psychiatry. 2016 Oct;57(10):1103-12
pubmed: 27647050
Int J Epidemiol. 2018 Feb 1;47(1):356
pubmed: 29190382
Int J Epidemiol. 2013 Feb;42(1):97-110
pubmed: 22507742
Hum Mol Genet. 2018 Apr 1;27(7):1301-1308
pubmed: 29365106
Clin Epigenetics. 2018 Jul 18;10(1):96
pubmed: 30021623
Aging (Albany NY). 2017 Feb 14;9(2):419-446
pubmed: 28198702
Psychoneuroendocrinology. 2018 Nov;97:131-134
pubmed: 30016711
Psychoneuroendocrinology. 2018 Jun;92:123-134
pubmed: 29452766
Epigenomics. 2018 Jun;10(6):707-722
pubmed: 29888956
Semin Cell Dev Biol. 2018 May;77:115-132
pubmed: 29017800
J Gerontol A Biol Sci Med Sci. 2020 Feb 14;75(3):473-480
pubmed: 31630168
Psychoneuroendocrinology. 2020 Mar;113:104484
pubmed: 31918390

Auteurs

Rosalind Tang (R)

Bristol Medical School, Faculty of Health Sciences, University of Bristol, 5 Tyndall Avenue, Bristol, BS8 1UD, UK. rt16358@bristol.ac.uk.
Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, Canada. rt16358@bristol.ac.uk.

Laura D Howe (LD)

MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.

Matthew Suderman (M)

MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.

Caroline L Relton (CL)

MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.

Andrew A Crawford (AA)

MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
BHF Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.

Lotte C Houtepen (LC)

MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH